Highest-materiality recent filing
Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront
Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.
Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.
Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted
DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.
Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing
Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.
Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M
Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.
Stockholders approved increase in authorized voting common stock from 20M to 100M shares.
Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025
Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.
Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025
Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.
Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study
Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.
Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction
Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.
Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4
Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.
Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024
Matthew McClure resigned as Chief Medical Officer on May 9, 2024.
Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024
Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.
Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024
Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.
On January 30, 2025, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Lesley Ann Calhoun as the Company’s Chief Operating Officer, effective immediately.
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
appointed Heather Preston, M.D. and Margarita Chavez, J.D., to the Board to fill the newly created directorships
The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after Mr. Nielsen’s resignation.
On May 9, 2024, Matthew McClure notified Aligos Therapeutics, Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company.
Max materiality 0.75 · Median 0.60 · Most common event earnings